These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35246200)

  • 1. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
    Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
    Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario?
    Fontrier AM; Kanavos P
    Value Health; 2023 Jul; 26(7):1011-1021. PubMed ID: 36889379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
    Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
    Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
    [No Abstract]   [Full Text] [Related]  

  • 4. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of the evolution in the access to orphan medicines in Spain].
    Mestre-Ferrándiz J; Iniesta M; Trapero-Bertran M; Espín J; Brosa M
    Gac Sanit; 2020; 34(2):141-149. PubMed ID: 31014554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug development for exceptionally rare metabolic diseases: challenging but not impossible.
    Putzeist M; Mantel-Teeuwisse AK; Wied CC; Hoes AW; Leufkens HG; de Vrueh RL
    Orphanet J Rare Dis; 2013 Nov; 8():179. PubMed ID: 24237580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.
    Vokinger KN; Kesselheim AS
    BMJ Open; 2019 Oct; 9(10):e028634. PubMed ID: 31601584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed access to treatments for rare diseases: who's to blame?
    Feltmate K; Janiszewski PM; Gingerich S; Cloutier M
    Respirology; 2015 Apr; 20(3):361-9. PubMed ID: 25722183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of patient access to orphan drugs in Turkey.
    Koçkaya G; Atalay S; Oğuzhan G; Kurnaz M; Ökçün S; Sar Gedik Ç; Şaylan M; Şencan N
    Orphanet J Rare Dis; 2021 Feb; 16(1):68. PubMed ID: 33549137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019.
    Badia X; Vico T; Shepherd J; Gil A; Poveda-Andrés JL; Hernández C
    Orphanet J Rare Dis; 2020 Aug; 15(1):224. PubMed ID: 32859228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report.
    Naipaul R; Marques C; Ng J; Barbour S; Lo C; Hildebrand AM; Siu V; Prasad B; Laurin LP; Wazny LD; Armstrong S; Tran J; Sheffield M; Jauhal A; Hladunewich MA
    Can J Kidney Health Dis; 2023; 10():20543581231190227. PubMed ID: 37581108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
    Fontrier AM
    Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020.
    Pham C; Le K; Draves M; Seoane-Vazquez E
    JAMA Intern Med; 2023 Apr; 183(4):290-297. PubMed ID: 36780147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
    Winstone J; Chadda S; Ralston S; Sajosi P
    Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
    Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare diseases and orphan drugs: Latvian story.
    Logviss K; Krievins D; Purvina S
    Orphanet J Rare Dis; 2014 Sep; 9():147. PubMed ID: 25231378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.